RFA-OD-27-004: INCLUDE Project Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)

RFA-OD-27-004: INCLUDE Project Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)

The NIH INCLUDE Project Transformative Research Awards are designed for teams with ambitious ideas that are high-risk, high-reward, and potentially paradigm-shifting in Down syndrome science. This NOFO is officially open in the 2026–2027 NIH cycle window and is one of the strongest examples of research funding where reviewer expectations are explicitly different from standard R01-style grants.

If your project idea is a safe, incremental follow-up to existing work, this may not be the right mechanism. If your idea is unconventional enough that it might create a new path for understanding Down syndrome biology, co-occurring conditions, or interventions, this is the right class of call to target.

Key details table

What this opportunity is and why it is distinct

NIH defines this NOFO as a transformative research channel. That label is not just branding. It changes how applications are expected to be written and evaluated.

A standard NIH proposal often rewards rigorous preliminary data and clear, incremental milestones. This call explicitly gives applicants room to propose bold logic without the expectation of extensive preliminary work. The NOFO explicitly says this is for projects with the potential to transform scientific paradigms, methods, or outcomes in Down syndrome-related research.

The NOFO also frames the program across the INCLUDE Project, a broad trans-NIH set of activities around Down syndrome, but this specific announcement is clearly scoped toward Component 1 type work: high-risk basic science and transformative projects with potential to change how the field is practiced. That is a hard point that many proposals miss. You are not applying for a traditional clinical trial pathway here. NIH explicitly says clinical trials are not acceptable for this specific NOFO.

At a practical level, this call is for applicants who can:

• identify a major gap in Down syndrome science, and
• propose a research strategy that is clearly different from prevailing approaches,
• justify the boldness without pretending all risks have already been resolved,
• and connect their idea to major potential impact in quality of life, mechanism, diagnosis, prevention, or treatment.

The page repeatedly contrasts this program with standard applications by emphasizing novelty, paradigm potential, and impact scale.

Why it is relevant for 2026/2027 planning

RFA-OD-27-004 is strongly relevant to your current planning window because it was posted in May 2026 and has multiple recurring cycles in the published timeline. The opportunity is not a single-date pass; it is structured around recurring submissions and review windows, including cycles extending into 2027.

For teams building an annual research calendar, this creates strategic flexibility:

• If your lab is not fully prepared by the first 2026 due date, a later cycle can still be used,
• If your first submission is weak on one specific criterion, you can strengthen it for the next cycle (subject to re-submission rules and no overlap constraints),
• You can recruit co-investigators and resources with a clear cycle horizon in mind.

That said, flexibility is not automatic acceptance. If your concept is too generic, if your submission is non-compliant, or if your team underprepares registrations and signatures, the NIH process will reject on mechanics long before science quality enters discussion.

Who fits this NOFO (and who should not apply)

Best-fit profiles

This opportunity is strongest for:

• labs with a strong conceptual idea where data gaps can be addressed through a novel mechanism,
• scientists proposing bold molecular, systems, computational, or translational ideas that challenge established assumptions,
• teams applying collaborative science with clear, measurable milestones for the transformative outcomes,
• investigators willing to present significance and logic plainly, without overloading with routine feasibility details,
• applicants who can build a coherent R01-style structure in which high innovation is the dominant feature.

Because NIH includes one of the largest possible sets of eligible U.S. entities in this NOFO, the fit decision is not usually institutional first; it is strategic fit first.

Who should avoid applying

If your project is primarily a clinical trial design, this is wrong. The NOFO explicitly excludes clinical trials for this announcement.

If your project is still at an exploratory stage but not strongly transformational, it may be out of scope or better suited to another NIH mechanism.

If your institution is not comfortable completing core compliance steps (SAM.gov, eRA Commons, required identifers, submission routing), skip the idea this cycle. Administrative failure in NIH systems can cost you eligibility regardless of scientific merit.

Eligibility and legal/compliance gates

The NOFO contains a broad entity list that includes:

• higher education institutions,
• nonprofits,
• for-profit and small business organizations,
• local governments,
• federal agencies,
• and a broader set of “other” entities.

In other words, this is not narrow in terms of applicant type. However, there are two compliance gates that often trip applicants:

1. Foreign subawards and foreign subcontracts are prohibited under this NOFO.
2. The PI ecosystem must still operate within NIH submission and profile standards.

You can still involve international collaboration as a non-funded component or via allowed consultative pathways, but you must not submit awarded structures that violate NIH’s foreign subaward restrictions in this specific announcement.

The NOFO states non-U.S. entities may be eligible in certain forms, and non-domestic components may be included, but monetary foreign subawards/subcontracts are explicitly disallowed.

Other compliance requirements include:

• PI(s) must have an eRA Commons account,
• PI profile must include linked ORCID,
• organizations should confirm submission permissions and roles before submission.

A practical point from the administrative text: if the PI is also the Signing Official, NIH requires two distinct eRA Commons accounts (organisational role and PI role).

Funds, budget, and award structure

The financial section of this NOFO is straightforward:

• NIH intent: about $3,000,000 committed across up to 4 awards per year in FY2027, FY2028, FY2029,
• Maximum direct costs: $500,000 per year,
• maximum project period: 5 years,
• no cost-sharing required.

This creates some useful planning implications:

• Even with strong innovation, your project budget should stay inside direct-cost structure and explain each cost in terms of major scientific output,
• Your budget narrative should emphasize why the proposal needs NIH support at the projected scale,
• You do not need to over-rotate toward matching finance if the idea is scientifically strong, but you still need credible execution.

Given that no preliminary data are required, teams sometimes overinflate budgets around exploratory work that is not yet conceptually anchored. A better strategy is to budget around milestones that are testable even in high-risk designs.

Application and submission mechanics

NIH is explicit that this NOFO requires strict adherence to the Research (R) Instructions and all publication-specific instructions. In practice, your preparation has three concurrent tracks:

1. Science track: define transformative rationale, approach, innovation, milestones.
2. Compliance track: registrations, roles, ORCID/eRA/organization readiness.
3. Systems track: route selection (ASSIST / Grants.gov Workspace / institutional S2S), form generation, internal submission testing.

The NOFO lists three submission paths:

• NIH ASSIST,
• institutional S2S through eRA Commons and Grants.gov,
• Grants.gov Workspace plus eRA Commons tracking.

What to include in the narrative section

The NOFO gives explicit guidance for the Research Strategy structure. Useful points:

• begin with a short overview of the project and why it matters,
• clearly define how the idea advances beyond current approaches,
• do not rely on extensive preliminary data as the backbone of feasibility,
• include key risks and fallback strategy,
• specify deliverable-style milestones to support claim of transformative potential,
• and justify why this belongs to Transformative Research rather than a regular R01 path.

The line that matters for every applicant: preliminary data are not required and in some cases, an overabundance of routine detail is not what this mechanism is looking for.

Timing behavior and review sequence

The NOFO includes published cycle tables with dates across 2026 and 2027. The practical sequence is:

• application due date(s),
• review windows,
• advisory council windows,
• anticipated start windows.

NIH also reminds applicants to submit early to leave room for correction. That warning is operationally significant: late-cycle technical errors can invalidate entire submissions before science is read. Do not wait to test the final form at 24 hours before deadline.

For teams pursuing this in the 2026/2027 window, plan backward from at least one published deadline and protect a buffer window for administrative fixes.

Review posture and what reviewers prioritize

The NOFO aligns with NIH peer review structure:

• scientific and technical merit,
• top-tier innovative scope,
• overall significance and appropriateness for this Transformative mechanism,
• and portfolio funding fit to NIH priorities.

The review system may not discuss all applications. NIH states generally only top applicants (often the upper segment after initial triage) move to full discussion.

For this NOFO, review strength usually comes from three things:

1. Clear transformative framing: not only what you are doing, but why this should change the field,
2. Logic strength with risk-aware execution: how you move from uncertainty to measurable outputs,
3. Down syndrome relevance: the connection to Down syndrome biology/co-occurring conditions must be explicit, not decorative.

Applications that sound merely incremental are common losers even when technically competent.

Application strategy for teams targeting this cycle

Build the concept into a decision-first document

A winning Transformative Research narrative usually starts from this question: what would have to change in the field if this succeeds? If you cannot answer that clearly in one paragraph, your application is likely too weak.

A practical structure:

• Problem statement: define one bottleneck, one measurable mechanism,
• Transformative move: what existing assumption your approach overturns,
• Approach: a lean plan showing how your team tests that move,
• Milestones: explicit 3–4 checkpoints with expected evidence outputs,
• Risk handling: what if plan A fails and what to do in month 8 or year 2,
• Impact statement: who benefits and how science or care changes.

Prepare for NIH’s strict mechanics

Do not treat registration as “admin cleanup.” In NIH NOFOs, admin often determines eligibility. Build a pre-submission checklist with owners:

• SAM.gov status,
• institutional signing official confirmation,
• eRA Commons account + role,
• ORCID linkage,
• final budget line-check against $500k/year cap,
• no prohibited foreign subcontract language,
• required letters and attachments included in correct system fields.

Internal review before submission

Use at least one internal dry-run:

• run a complete package build in your chosen submission route,
• cross-check every mandatory section in the Research (R) instructions,
• have non-PI staff verify compliance fields,
• verify all institutional signatures and affiliations,
• submit early enough for recovery.

Common mistakes and prevention

Mistake 1: treating it like a standard discovery R01

Not every R01-like structure is accepted in spirit. This NOFO is transformative-first. If your aims are too conventional, it reads as a weak fit.

Fix: explicitly map each aim to a hypothesis that is clearly different from existing trajectories.

Mistake 2: over-emphasizing preliminary data while under-explaining novelty

This NOFO explicitly removes preliminary data as a gate condition.

Fix: make innovation, rationale, and paradigm-shift potential the backbone, then use limited data only where absolutely necessary.

Mistake 3: ignoring foreign subaward restrictions

Teams occasionally include planned international collaborations that are structurally foreign-subsidized in ways the NOFO excludes.

Fix: review collaboration architecture and convert disallowed flows into allowed non-monetized collaboration mechanisms.

Mistake 4: weak milestone logic

Because it is called Transformative, milestones are more important than routine task checklists.

Fix: build a milestone map with measurable outputs (not just intention statements).

Mistake 5: waiting until the final week to resolve registrations

Late submission usually reveals PI/organization-level failures.

Fix: complete registrations by your internal minus-8-week checkpoint and test all systems.

FAQ

Does this require a domestic-only applicant?

The NOFO allows broad eligibility and includes U.S. and certain non-domestic participation, but it is explicit that no foreign subawards/subcontracts are allowed on awards from this mechanism.

Is clinical trial funding available?

No. The opportunity title and instruction text explicitly mark this as R01 Clinical Trial Not Allowed. Applications that meet clinical trial criteria should be considered against other announcements.

Do I need preliminary data?

No. NIH explicitly says no preliminary data are required, though limited data can be included if useful.

Is cost sharing required?

No, this NOFO does not require cost sharing.

What is the maximum budget?

Up to $500,000 direct costs per year, with award cycle limits and annual/yearly planning constraints in place.

How many times can we submit?

The NOFO lists recurring cycles through multiple review windows. Organizations can submit multiple applications if they are scientifically distinct and not overlapping, subject to NIH overlapping application rules.

Practical next steps for 2026/2027 applicants

1. Confirm your team’s fit to Transformative scope before writing a full draft.
2. Finalize institutional and PI registration status now (eRA Commons, ORCID, SAM.gov, internal routing).
3. Select one submission cycle (first feasible cycle is often strongest; later cycles can be used for refinement).
4. Build your narrative around the section prompts: Overview, Approach, Innovation, Transformative alignment, milestones.
5. Run an internal compliance dry run in ASSIST or your S2S workflow.
6. Submit early enough to avoid system corrections under deadline pressure.

This route is not about quantity. It is about whether your idea is genuinely worth the risks a reviewer is being asked to fund.

Official links

• Official NOFO: RFA-OD-27-004 Full Announcement
• NIH Assistant/guide references listed in the NOFO: How to Apply - Application Guide
• NIH Guide for Grants and Contracts: https://grants.nih.gov/grants/guide/notice-files/
• INCLUDE Project information: https://www.nih.gov/include-project
• eRA Service Desk (submission technical support): https://era.nih.gov
• Grants.gov Support Center: https://www.grants.gov

The opportunity is technical, competitive, and worth targeting only if your proposal is genuinely high-variance and high-value in the Down syndrome field.